Sacubitril/Valsartan in Heart Failure With Reduced Ejection Fraction Patients: a Real World Study in India
Latest Information Update: 23 May 2023
At a glance
- Drugs Sacubitril/valsartan (Primary)
- Indications Heart failure
- Focus Therapeutic Use
- Sponsors Novartis Pharmaceuticals
- 20 Sep 2022 Status changed from active, no longer recruiting to completed.
- 26 Oct 2021 Planned End Date changed from 31 Aug 2021 to 2 May 2022.
- 26 Oct 2021 Planned primary completion date changed from 31 Aug 2021 to 2 May 2022.